InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-24.5%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Geffken Daniel E., Chief Financial Officer. Director active across 3 companies, notably Eloxx Pharmaceuticals, Inc.. Aggregated, 4 reports have been recorded. Breakdown: 1 buy · 0 sell. Total volume traded: €32k. Activity tracked since 29 November 2021. The latest transaction was filed on 23 August 2023 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Geffken Daniel E.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
10,002 sharesClass A Common StockSEC:0001213900-24-015030:0
2,033 shares0Common StockSEC:0001437749-23-024844:0
5,000 shares0Common StockSEC:0001437749-22-014714:0
50,000 shares@ US$0.7250.0% of flowCommon StockSEC:0001415889-21-005600:0
Canonical exit: 27 Feb 2022 (T+90)
4 of 4 declarations
About Geffken Daniel E.
Daniel E. Geffken is the Interim Chief Financial Officer and Board Member at Eloxx Pharmaceuticals, Inc. and Windtree Therapeutics Inc. /DE/. He oversees the financial operations of both companies and is responsible for financial planning and risk management. His expertise is crucial in ensuring the financial health of these organizations.
